Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Hematological Disorders Clinical Trials

A listing of Hematological Disorders medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (26) clinical trials

Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation

Primary Objectives: Feasibility of generating activated PTCy-MILs in patients with relapsed disease involving the bone marrow. Toxicity of PTCy-MILs, specifically the rate of grade III-IV acute GVHD within the first 90 days after PTCy-MIL infusion. Secondary Objectives Determination of an optimal safe dose for PTCy-MILs. Immunologic characterization of the PTCy-MIL …


A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies

This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended phase two dose (RPTD), and evaluate the safety, efficacy, and pharmacokinetic (PK) profile of ABBV-621 for participants with previously-treated solid tumors or hematologic malignancies.


In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM)

Alpha thalassemia major (ATM) is almost universally fatal in utero and represents an orphan disease with an unmet need for effective therapies. The only current treatment to allow the fetus to be born is to perform in utero transfusions (IUT) of red blood cells to treat the anemia and avoid …


VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies

This is a phase I trial for safety of VPA expanded cord blood stem cells in patients with hematological malignancies undergoing allogeneic stem cell transplantation. The primary endpoint of the study is safety as defined by the incidence of infusion reactions and graft failure, lack of neutrophil engraftment by day …


A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF)

Primary Objective: To determine dose-limiting toxicity of CK0801 as defined as any of the events each start at the time of CK00801 infusion Severe (grade 3 or 4) infusion toxicity within 24 hours (NCI-CTCAE V4.0) Regimen related death within 30 days Severe (grade 3 or 4) Cytokine Release Syndrome within …


Phase I Study of CTL Anti-DP Infusion Post-hematopoietic Stem Cell Transplantation

Rationale Despite graft-versus-tumor effect, relapse remains one of the main causes of morbidity and mortality in allo-HSCT recipients. Forty to 50% of deaths following allo-HSCT are due to disease relapse. In case of relapse, the prognosis is very poor and disease burden remains a challenge for the use of adoptive …